Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.

McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY.

Bone Marrow Transplant. 2011 Jan;46(1):27-33. doi: 10.1038/bmt.2010.60.

PMID:
20305698
3.

Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.

Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, Przepiorka D, Mezzi K, Kletzel M; Pediatric Blood, Marrow Transplant Consortium..

Pediatr Blood Cancer. 2010 Feb;54(2):291-8. doi: 10.1002/pbc.22227.

PMID:
19743300
4.

Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.

Soni S, Gross TG, Rangarajan H, Baker KS, Sturm M, Rhodes M.

Pediatr Blood Cancer. 2014 Sep;61(9):1685-9. doi: 10.1002/pbc.25059.

PMID:
24740582
5.

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.

Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98.

6.

New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.

Gaziev J, Isgrò A, Mozzi AF, Petain A, Nguyen L, Ialongo C, Dinallo V, Sodani P, Marziali M, Andreani M, Testi M, Paciaroni K, Gallucci C, De Angelis G, Alfieri C, Ribersani M, Lucarelli G.

Pediatr Blood Cancer. 2015 Apr;62(4):680-6. doi: 10.1002/pbc.25376.

PMID:
25557687
7.

Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.

Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M.

Bone Marrow Transplant. 2009 Aug;44(3):145-56. doi: 10.1038/bmt.2008.437.

PMID:
19182832
8.

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.

Bone Marrow Transplant. 2001 Oct;28(8):743-51.

9.

Association of busulfan area under the curve with veno-occlusive disease following BMT.

Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R.

Bone Marrow Transplant. 1996 Feb;17(2):225-30.

PMID:
8640171
10.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

PMID:
12374451
11.

Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.

Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB.

Blood. 1992 Nov 1;80(9):2425-8.

12.

Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.

Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.

Biol Blood Marrow Transplant. 2010 Jun;16(6):818-23. doi: 10.1016/j.bbmt.2010.01.002.

13.

Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.

Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA.

Bone Marrow Transplant. 2011 Jan;46(1):84-9. doi: 10.1038/bmt.2010.55.

PMID:
20305699
14.

Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience.

Majumdar S, Robertson Z, Robinson A, Starnes S, Iyer R, Megason G.

Bone Marrow Transplant. 2010 May;45(5):895-900. doi: 10.1038/bmt.2009.244.

PMID:
19784079
15.

Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.

Bernaudin F, Souillet G, Vannier JP, Plouvier E, Lemerle S, Michel G, Bordigoni P, Lutz P, Kuentz M.

Bone Marrow Transplant. 1993;12 Suppl 1:118-21.

PMID:
8374551
16.

Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.

Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.

Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14.

17.
18.

Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.

Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.

Am J Hematol. 2007 Oct;82(10):873-80.

19.

Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.

Torjemane L, Ladeb S, Ben Othman T, Abdelkefi A, Lakhal A, Ben Abdeladhim A.

Pediatr Blood Cancer. 2006 Apr;46(4):496-500.

PMID:
16333862
20.

Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.

Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1447-54. doi: 10.1016/j.bbmt.2009.07.014.

Items per page

Supplemental Content

Support Center